ROTEM Interpretation Software for Hemostatic Disorders
NS
JS
Overseen ByJacob Steenblik
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Utah
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to assess a novel rotational thromboelastometry (ROTEM®) interpretation software to determine whether its use improves the accuracy of clinician interpretation.
Eligibility Criteria
This trial is for current residents and attending physicians in the University of Utah's Department of Anesthesiology, who have varying levels of experience with thromboelastography. Those not actively part of this department or unwilling to consent are excluded.Inclusion Criteria
People who work at the University of Utah Department of Anesthesiology and have different levels of experience with a test called thromboelastography.
Exclusion Criteria
No longer an active member of the University of Utah Department of Anesthesiology
Refusal to consent
Treatment Details
Interventions
- Novel ROTEM interpretation software
Trial OverviewThe study is evaluating a new software designed to help doctors interpret ROTEM (rotational thromboelastometry) tests more accurately. These tests measure how well blood clots in patients with clotting disorders.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Software TutorialExperimental Treatment1 Intervention
Participants will be asked to interpret a series of ROTEM studies before and after a tutorial on a novel ROTEM interpretation software.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Utah
Lead Sponsor
Trials
1,169
Recruited
1,623,000+
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.